BSF Enterprise signs 10-year global cosmetics deal for bioactive peptides

Emma James 08/13/2026

A Peptide Partnership Unlocks Global Beauty Secrets

In a strategic move poised to redefine the intersection of biotechnology and luxury beauty, BSF Enterprise has forged a landmark ten-year partnership with German consultancy SCHAKAU Managementberatung. This exclusive deal focuses on bringing ETSYL, a potent bioactive peptide, into the global cosmetics and skincare market.

ETSYL, scientifically known as palmitoyl pentapeptide-87, is far more than just a chemical compound; it represents a powerful ingredient with roots in advanced tissue engineering. Research suggests that this peptide holds significant promise for enhancing collagen production, opening exciting avenues for revolutionary skincare applications.

The collaboration centers on commercializing this potential, transforming scientific discovery into tangible luxury products. SCHAKAU will receive the exclusive rights to commercialize, distribute, and license ETSYL worldwide, ensuring its reach across the most discerning markets.

For the cosmetics industry, this partnership offers a unique opportunity. SCHAKAU plans to integrate ETSYL as a core active ingredient in their prestigious HANDS OF GOD luxury skincare brand, while simultaneously pursuing licensing agreements with a wider range of cosmetic companies. This strategy positions the peptide not just as an ingredient, but as a globally recognized cosmetic powerhouse.

The financial and operational framework of the agreement is equally strategic. To ensure credibility and success in the competitive market, SCHAKAU has allocated approximately €300,000. This investment will be directed toward essential steps including clinical claim substantiation, rigorous regulatory compliance, brand development, and international distribution.

BSF Enterprise remains at the core of this innovation. While granting extensive commercial rights, BSF retains full ownership of the underlying intellectual property. Furthermore, its subsidiary, 3D Bio-tissues, will manage the manufacturing and supply of the ingredient, ensuring quality control from the source.

The structure is designed to be capital-light for BSF, allowing the company to access the global market efficiently by transferring much of the burden of commercial development and testing to its partners. This strategic approach allows BSF to focus on innovation while leveraging external expertise for global scaling.

Ultimately, this deal establishes a powerful pathway for ETSYL to transcend its initial applications, establishing the peptide as a recognized and marketable cosmetic active. By fostering third-party licensing, the partnership aims to broaden ETSYL’s impact far beyond a single luxury brand, cementing its place as a foundational element in the future of beauty science.